Context Therapeutics (CNTX) to Release Earnings on Wednesday

Context Therapeutics (NASDAQ:CNTX) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Wednesday, August 6th. Analysts expect Context Therapeutics to post earnings of ($0.06) per share for the quarter.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05). On average, analysts expect Context Therapeutics to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Context Therapeutics Trading Down 2.4%

Shares of Context Therapeutics stock opened at $0.83 on Wednesday. The company has a 50 day moving average of $0.68 and a 200-day moving average of $0.77. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $2.75. The company has a market cap of $74.45 million, a PE ratio of -2.68 and a beta of 1.88.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on CNTX. Piper Sandler reaffirmed an “overweight” rating and set a $4.00 price target (down previously from $4.50) on shares of Context Therapeutics in a report on Thursday, June 26th. D. Boral Capital reaffirmed a “buy” rating and set a $9.00 price target on shares of Context Therapeutics in a report on Thursday, May 8th. Finally, William Blair reaffirmed an “outperform” rating on shares of Context Therapeutics in a report on Tuesday, April 29th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Context Therapeutics currently has a consensus rating of “Buy” and an average price target of $5.50.

Insider Buying and Selling

In related news, CEO Martin A. Lehr acquired 100,000 shares of the stock in a transaction that occurred on Monday, June 9th. The stock was acquired at an average cost of $0.70 per share, for a total transaction of $70,000.00. Following the transaction, the chief executive officer directly owned 920,190 shares in the company, valued at $644,133. This trade represents a 12.19% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Jennifer Lynn Minai-Azary acquired 40,010 shares of the stock in a transaction that occurred on Friday, June 6th. The shares were bought at an average price of $0.64 per share, with a total value of $25,606.40. Following the completion of the transaction, the chief financial officer owned 80,010 shares in the company, valued at $51,206.40. This represents a 100.03% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 160,010 shares of company stock valued at $107,206. 3.04% of the stock is owned by corporate insiders.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.